Sickle Cell Transplant Outcomes: Evidence for a Cure

Bone marrow transplant, more precisely allogeneic haematopoietic stem cell transplant, is the one curative treatment for sickle cell disease that is widely available to patients today. For sickle cell transplant outcomes, Dr. Dharma Choudhary, Chairman - Haemato Oncology & BMT, BLK-Max Super Speciality Hospital, New Delhi, India, reports 83% overall survival across his 65 sickle cell transplants. Most patients who cross the first three to six months after transplant remain cured.

That figure was achieved in a population that usually arrives late, often as adults with established organ damage, and in which more than half of the transplants used a half-matched family donor. This guide sets out why sickle cell disease warrants a curative approach, what a transplant actually involves, the outcomes that can be expected and how transplant compares with gene therapy and newer drugs. Three companion articles go deeper: when to refer a patient for transplant, donor choice, HLA matching and conditioning, and complications, GVHD and follow-up after the patient returns home.

Why sickle cell disease needs a cure, not only control

Sickle cell disease needs a cure because it damages organs progressively and shortens life, while standard drug treatment only controls it. It is caused by a single base-pair mutation in the beta-globin gene. The abnormal haemoglobin it produces polymerises when it gives up oxygen, distorting red cells into the characteristic sickle shape. Sickled cells die early and block small vessels, so the disease combines severe chronic anaemia with repeated episodes of vessel blockage (vaso-occlusive crises) that damage organs over time.

Dr. Choudhary opened the session with the scale of that damage. In the United States, life expectancy with sickle cell disease is about 52 years, more than 20 years shorter than in the general population, and about one in 365 Black or African American births results in sickle cell disease. In Nigeria alone, almost 150,000 children are born with the condition every year. The disease is not confined to Africa and its diaspora: India has its own sickle cell belt, and Dr. Choudhary described the condition as a worldwide problem.

The long-term injury is broad. Strokes, silent cerebral infarcts and cognitive dysfunction affect the brain; acute chest syndrome and pulmonary hypertension affect the lungs and, eventually, the right side of the heart; kidney damage, infection after loss of splenic function, avascular necrosis of bone and iron overload from repeated transfusion complete the picture. The pattern of organ damage, and why it should drive the timing of referral, is covered in detail in the referral article.

The disease is also heterogeneous. Some patients have one crisis a year or none, while others are admitted again and again. Dr. Choudhary's position is that a transplant is curative for a selected group of patients with severe disease, and that in the long run it brings an economic benefit as well as substantially improving quality of life.

Carriers and asymptomatic patients

Two groups are often confused. A sickle cell carrier has one affected gene and is generally healthy, but can pass the gene on; a child develops sickle cell disease when both parents are carriers. Asked during the Live Discussion whether anything can be done for asymptomatic patients, Dr. Choudhary was unequivocal: where there is no phenotypic expression of the genotypic disorder, no treatment is warranted. Many mild patients reach adulthood and live normal lives, and every treatment carries a risk of morbidity and mortality.

What current medicines can and cannot do

Current drugs reduce crises and complications in some patients, but none of them cures sickle cell disease. Standard management of sickle cell disease is supportive: prophylactic antibiotics, pain control, blood transfusion and hydroxyurea. Hydroxyurea raises fetal haemoglobin (HbF), which interferes with sickling, and clinical trials show that it reduces the number of crises and, in some patients, the risk of stroke.

Dr. Choudhary traced how slowly the drug pipeline has moved:

• 1998: hydroxyurea, the first approved disease-modifying drug.
• 2017: L-glutamine, almost 20 years later.
• 2019: crizanlizumab and voxelotor.
• 2023: the first gene therapies.

Two of these later drugs have since run into difficulty. Voxelotor was withdrawn from markets worldwide by its manufacturer in September 2024 because of safety concerns, and the European Medicines Agency revoked crizanlizumab's authorisation in 2023 after a confirmatory trial did not show a reduction in crises.

None of these drugs cures the disease. Chronic transfusion and other supportive therapy help prevent stroke but, as Dr. Choudhary stressed, they are not curative, and long-term transfusion brings its own problems in red cell alloimmunisation (antibodies against donor blood) and iron overload. His summary was direct: what is available to everyone today as a cure is allogeneic stem cell transplant, while best supportive care leaves patients with a high risk of illness and early death.

Yet only a small fraction of eligible patients receive a transplant. Dr. Choudhary attributed this to three gaps: the lack of a suitable donor, a lack of information, and limited understanding of what transplant involves.

What a bone marrow transplant actually is

A bone marrow transplant replaces a patient's blood-forming (haematopoietic) stem cells with healthy ones. In sickle cell disease the defect sits in these stem cells, which is why replacing them cures the disease: once donor cells have repopulated the marrow, the patient's blood is produced from donor stem cells.

Dr. Choudhary drew several distinctions that referring doctors often find confusing:

• By stem cell source. Cells collected from bone marrow give a bone marrow transplant; cells collected from the bloodstream give a peripheral blood stem cell transplant; cells from umbilical cord blood give a cord blood transplant. Historically, marrow was harvested from the back of the pelvis (the posterior iliac crest) and infused into the recipient through a vein.
• By donor. An allogeneic transplant uses another person's cells: a matched sibling, a half-matched (haploidentical) relative, or an unrelated donor found through a registry.
• Autologous transplant uses the patient's own stem cells to rescue the marrow after high-dose chemotherapy. It carries little transplant-related mortality, no rejection and no graft-versus-host disease, and is used for multiple myeloma and lymphoma. On its own it cannot cure sickle cell disease, because the patient's own unmodified stem cells carry the defect.

He also corrected a common misconception: a bone marrow transplant is a medical procedure, not a surgical one. It is not "cut and paste" like a liver or kidney transplant. The stem cells are infused through a vein, and the outcome depends on the medicines used before, during and after the infusion.

The modern field began after the Second World War, and E. Donnall Thomas received the 1990 Nobel Prize in Physiology or Medicine for his pioneering work on bone marrow transplantation. The transplant itself runs in three phases, preparation (conditioning), the day of stem cell infusion, and the wait for engraftment, which are explained in the donor and conditioning article.

Sickle cell transplant outcomes: what the evidence shows

Matched sibling donor transplant remains the benchmark. In the data Dr. Choudhary presented, it achieves disease-free survival (alive and free of sickle cell disease) of 85% and overall survival of 97%, with follow-up extending to around 15 years, so most patients are cured. The risks he set against this were graft rejection (failure of the donor cells to take hold) in 7 to 10% of patients and transplant-related mortality (death caused by the treatment rather than the disease) of around 5%.

Haploidentical transplant, using a half-matched parent, sibling or other relative, has changed most. Early attempts with non-myeloablative regimens had higher rejection rates. With the current platforms, Dr. Choudhary said, rejection is now around 5 to 10%, close to matched sibling transplant, and overall survival in current data sets approaches that of matched sibling transplant at around 80 to 90%. Long-term haploidentical results from a colleague who previously worked with him reached about 90%. His conclusion: today the donor type does not, in practice, decide the outcome.

Age at transplant does. Early transplant brings better outcomes and fewer complications, and Dr. Choudhary pointed to an observation by Eliane Gluckman, the French haematologist who performed the first cord blood transplant: matched sibling transplant performed at an early age with bone marrow as the stem cell source gives five-year overall survival above 95%. Her argument, which he endorsed, was that with survival at that level there is no need for controlled trials comparing transplant with chronic transfusion or hydroxyurea, and that paediatric haematologists too often meet reluctance from other haematologists to refer patients.

Results from Dr. Choudhary's programme

A few months before the session, Dr. Choudhary analysed his programme's results. The programme had performed close to 1,500 to 1,600 transplants, including more than 270 haploidentical transplants. Its sickle cell series comprised 65 transplants:

Overall survival was 83%. Dr. Choudhary placed that figure in context: most of these patients arrived with comorbidities, after late referral and often already alloimmunised from transfusions, and more than half needed a haploidentical donor. On that basis he regards the outcomes as broadly equal to those reported elsewhere in the world.

Does race affect transplant outcome?

No. African patients tend to have more severe disease than Indian patients, so the presentation differs, but in Dr. Choudhary's experience the outcome of transplant does not. What determines outcome is a combination of patient factors (disease stage and comorbidity), donor factors (full match, half match or mismatch) and treatment factors. With the right conditioning, the right immunosuppression and the right supportive care, he argued, outcomes are similar across the globe, whether the transplant is done in America, Tokyo or India.

Reading a success rate

Families often ask which side of a percentage their child will fall on. Dr. Choudhary's answer is that statistics are for doctors. A percentage only exists across 100 patients; for the individual the outcome is binary. A quoted 99% success rate means nothing to the patient who lands in the 1%, and a patient who falls within a 30% success rate is cured. The risk to life that every transplant carries, and how families should weigh it, is discussed in the referral article.

Transplant versus gene therapy

Two gene therapies for sickle cell disease were approved in the United States in December 2023: one edits the patient's own stem cells to switch fetal haemoglobin back on, the other adds a functioning anti-sickling globin gene. Both use the patient's own cells, so no donor is needed, but both still require high-dose conditioning chemotherapy.

Dr. Choudhary reviewed a systematic comparison of the two approaches. Of the studies screened, 56 representing almost 1,200 patients met the inclusion criteria. The overall quality of evidence was low and there were no randomised controlled trials. Two-year overall survival after stem cell transplant was 91%, and acute chest syndrome and vaso-occlusive episodes fell after both stem cell transplant and gene therapy. A formal meta-analysis was not possible because there was no comparator, and the authors called for standardised reporting of disease-related complications and patient-reported outcomes.

His reading of that evidence is that gene therapy will not have a major advantage over transplant. For the patient in front of a referring doctor today, allogeneic transplant is the curative option with long-term follow-up data behind it.

Where the field is moving

Transplant for sickle cell disease is still evolving on three fronts, according to Dr. Choudhary:

1. Conditioning. Safer regimens are extending transplant to older and less fit patients.
2. Alternative donors. Haploidentical transplant has largely removed the "no donor" barrier for patients with a parent or other relative.
3. Stem cell collection. Growth factor used to mobilise stem cells into the blood can trigger a sickle crisis. Plerixafor, a mobilising drug that works by a different mechanism, is now a good alternative.

As success and survival rates improve in both children and adults, the short- and long-term risks of transplant have to be weighed against currently approved therapies for each patient.

Sickle cell transplant cost: why it differs between countries

Dr. Choudhary's figure is that transplant at his centre costs roughly one-fifth of the cost in the United States or the United Kingdom, and perhaps one-tenth when compared with the United States. He was careful about where the difference comes from. Good medicines cost much the same in most places, apart from local taxes. The savings lie in hospital and bed charges, which are lower across Asia than in America and Europe, and in supportive care and healthcare consumables, which are cheaper. Treatment costs also track each country's GDP, so comparing countries on price alone misleads.

His advice to African families who travel is to choose the best centre they can reach, where treatment can be given without compromise, and never to choose on price alone. A transplant offered at half the usual cost usually means something essential has been removed, a point explained in the article on complications and GVHD. Indicative package ranges are listed on the treatment-cost pages for matched sibling donor BMT and haploidentical BMT.

How to use this series

• Referring doctors deciding whether and when to refer should start with when to refer sickle cell disease for bone marrow transplant, which covers the guideline indications, age limits and who is not a candidate.
• Families waiting for HLA results will find donor options, HLA typing and conditioning explained in haploidentical versus sibling donor transplant.
• Patients preparing to return home and their local doctors should read complications and follow-up after a sickle cell transplant.

Dr. Choudhary's colleague Dr. Divya Doval covers diagnosis and day-to-day management of the disease in her own guide to the diagnosis and management of sickle cell disease. More haematology content is collected on the haematology specialty page.